ClinicalTrials.gg
RecruitingNCT05990764Updated Nov 18, 2023

Effects of a Combination of Polyphenol-rich Extracts, Prebiotics, and Hydrolyzed Fiber on the Quality of Life of Patients With Irritable Bowel Syndrome (IBS)

An interventional study of Probiotic, Prebiotic, Polyphenol-rich Extracts and Probiotic, Prebiotic in IBS - Irritable Bowel Syndrome, sponsored by AronPharma Sp. z o. o.. Recruiting at 1 site in Poland. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by AronPharma Sp. z o. o. · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2024, 2 years 9 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing probiotic in Irritable Bowel Syndrome — 2 open to participants now, 3 under way, none of them phase 3. Probiotic · Irritable Bowel Syndrome.

Planned enrollment
10th of 16
48 · median 93
Started
2023
with 3 others
No phase
10 of 16
2 open now
Registered
13th of 16
by date
Lead sponsor
1 of 16
AronPharma Sp. z o. o.

Among the 16 studies testing probiotic in Irritable Bowel Syndrome, this one is the 10th largest by planned enrollment, is one of 4 that started in 2023, is one of 10 with no phase, and was the 13th registered.

Irritable Bowel Syndrome

1,121 studies on the registry are indexed under Irritable Bowel Syndrome; 212 are open to participants now.

Browse Irritable Bowel Syndrome studies →

Open to participants now

2 of the 16 studies testing probiotic in Irritable Bowel Syndrome are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About probiotic

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 131 Irritable Bowel Syndrome studies recruiting now, 35 (27%) set no upper age limit and 86 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing probiotic in Irritable Bowel Syndrome, or all of them as a file.
02

Study summary

The aim of the study is to demonstrate a beneficial effect in reducing symptoms that negatively affect the quality of life of IBS patients, and to demonstrate a positive effect on inflammatory and intestinal function markers.

Read the detailed description

The double-blind, randomized, placebo-controlled study will be conducted on 48 patients (18-55 years old) with Irritable Bowel Syndrome (IBS). The study will consist of 2 months of supplementation with three parallel arms: 1) probiotic strains and prebiotic (Partially Hydrolyzed Guar Gum); 2) probiotic strains, prebiotic (Partially Hydrolyzed Guar Gum) and elderberry and chokeberry fruit extract; 3) placebo.The study will assess symptoms associated with IBS, using the IBS-QOL questionnaire and the Bristol Stool Formation Scale. Markers of inflammation and intestinal barrier permeability , will be determined in blood and stool samples collected from patients.

03

Conditions studied

  • IBS - Irritable Bowel Syndrome

Keywords

  • IBS
  • Gastrointestinal diseases
  • Probiotic
  • Prebiotic
  • Plant extract
  • Polyphenol-rich Extracts
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed Irritable Bowel Syndrome.
  • Women and men, 18-55 years old.
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Intake of supplements containing plant extracts, polyphenols or anthocyanins, and supplements containing fiber, probiotics and prebiotics.
  • Participation in another clinical trial.
  • Inability to swallow an oral study drug/placebo.
  • Oncological disease, disease, severe liver dysfunction, tuberculosis, leukemia, multiple sclerosis, AIDS, rheumatoid arthritis, organ transplant and other gastrointestinal diseases that may affect the results of the study.
  • Women who are pregnant, planning to become pregnant during the study, or breastfeeding,
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Probiotic, Prebiotic, Polyphenol-rich Extracts

    18 patients with IBS

    Dietary Supplement: Probiotic, Prebiotic, Polyphenol-rich Extracts

  • Experimental
    Probiotic, Prebiotic

    18 patients with IBS

    Dietary Supplement: Probiotic, Prebiotic

  • Placebo comparator
    Placebo

    18 patients with IBS

    Other: Placebo

Interventions

  • Dietary supplementProbiotic, Prebiotic, Polyphenol-rich Extracts

    probiotic strains, prebiotic (Partially Hydrolyzed Guar Gum) and elderberry and chokeberry extract Once a day

  • Dietary supplementProbiotic, Prebiotic

    Drug pages: ProbioticStudies of ProbioticProbiotic pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PrebioticsStudies of PrebioticsPrebiotics pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    probiotic strains, prebiotic (Partially Hydrolyzed Guar Gum) Once a day

  • OtherPlacebo

    placebo Once a day

06

What researchers measure

Primary outcomes

  1. IBS-QoL (Irritable Bowel Syndrome-Quality of Life) index

    IBS-QoL measures the impact of the disease on the quality of life of patients with IBS

    Time frame: Baseline, 2 months

  2. Stool consistency

    Will be assessed using the Bristol Stool Chart

    Time frame: Baseline, 2 months

Secondary outcomes

  1. Zonulin

    Zonulin level in stool samples

    Time frame: Baseline, 2 months

  2. Short-chain fatty acids

    Short-chain fatty acids level in stool samples

    Time frame: Baseline, 2 months

  3. IL-6

    IL-6 level in serum samples

    Time frame: Baseline, 2 months

  4. IL-8

    IL-8 level in serum samples

    Time frame: Baseline, 2 months

  5. I-FABP

    I-FABP level in serum samples

    Time frame: Baseline, 2 months

07

Study locations

1 of 1 sites recruiting
  • Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu
    Poznań, Poland
    Recruiting
    • Barbara Khaidakov, PhD · Contactbarbara.khaidakov@aronpharma.pl · 798 210 651
    • Dorota Mańkowska-Wierzbicka, MD, PhD · Principal investigator
    • Liliana Łykowska-Szuber, MD, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for Jan 2024, 8 months after the start.

Of 52 industry-sponsored interventional studies with no phase under Irritable Bowel Syndrome, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 8 months is below that.

Counting every sponsor, half of 360 studies reached it within 19 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2023
First posted
Aug 14, 2023
StartActual
May 8, 2023
Primary completionEst.
Jan 31, 2024
CompletionEst.
Jan 31, 2024
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05990764
Lead sponsor
AronPharma Sp. z o. o.
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
May 8, 2023
Primary completion
Jan 31, 2024 (estimated)
Completion
Jan 31, 2024 (estimated)
Last update
Nov 18, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Probiotic · Prebiotics

Start the discussion